Abstract: Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing ?v?3 and ?v?5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin.

Abstract: Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing ?v?3 and ?v?5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin.

Abstract: The component ‘drug’ new molecule for combining metals into complexes through a ring structure (DOTA) or linear structure, and a radionuclidic component, and chelating agent wherein embodiments may include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing ?v?3 and ?v?5 integrins, second component for combining metals into complexes through a ring or linear structure, and one or more radionuclidic components, a chelating agent for diagnosis and/or therapy (theranostic) in which the embodiments further include a anti-integrin peptidomimetic for precision medicine for cancers expressing ?v?3 and ?v?5 integrins.

Abstract: The present invention provides an in vivo imaging method that facilitates the diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG) at an early stage. Early diagnosis is particularly advantageous as neuroprotective treatment can be applied to healthy neural cells to delay or even prevent the onset of debilitating clinical symptoms. The present invention also provides methods for producing an in vivo imaging agent useful for early diagnosis of DIPG, where embodiments of the imaging agent include a lipophilic azomycin-based hypoxic cell sensitizer labelled with an in vivo imaging moiety, and embodiments including [18F]FMISO as the lipophilic azomycin-based hypoxic cell sensitizer labelled with an in vivo imaging moiety.

Abstract: The present invention provides an in vivo imaging method that facilitates the diagnosis of Acute Lymphoblastic Leukemia (ALL) at an early stage. Early diagnosis is particularly advantageous as a tool to select more aggressive therapy, to estimate the success rate for visualizing ALL at the time of diagnosis.

Abstract: A method of producing an isotope comprising directing electrons at a converting material coated with a coating material, the coating material having an atomic number of n, whereby interaction of the electrons with the converting material produces photons, and whereby the photons produced interact with the coating material to produce an isotope having an atomic number of n−1. In preferred embodiments, the converting material is Tungsten, the coating material having an atomic number of n is Radium-226, and the isotope having an atomic number of n−1 is Radium-225.

Abstract: Disclosed is a is an improved flood source, and method of making the same, which emits an evenly distributed flow of energy from a gamma emitting radionuclide dispersed throughout the volume of the flood source. The flood source is formed by filling a bottom pan with a mix of epoxy resin with cobalt-57, preferably at 10 to 20 millicuries and then adding a hardener. The pan is secured to a flat, level surface to prevent the pan from warping and to act as a heat sink for removal of heat from the pan during the curing of the resin-hardener mixture.

Abstract: A method of producing an isotope comprising directing electrons at a converting material coated with a coating material, the coating material having an atomic number of n, whereby interaction of the electrons with the converting material produces photons, and whereby the photons produced interact with the coating material to produce an isotope having an atomic number of n−1. In preferred embodiments, the converting material is Tungsten, the coating material having an atomic number of n is Radium-226, and the isotope having an atomic number of n−1 is Radium-225.

Abstract: A metal stent for vascular implantation comprising a generally tubular structure whose external surface is adapted to engage the interior vascular surface when implanted, said metal of said stent containing a substantially uniform dispersion of from about 0.05 to about 10.00 percent by weight of one or more naturally occurring or enriched stable isotopes having a half-life of less than two months and that are principally beta particle emitters, so that when activated, said stent emits low to moderate dosages of radiation uniformly to reduce cell proliferation.

Abstract: A metal stent for vascular implantation comprising a generally tubular structure whose extend surface is adapted to engage the interior vascular surface when implanted, said metal of said stent containing a substantially uniform dispersion of from about 0.05 to about 10.00 percent by weight of one or more naturally occurring or enriched stable isotopes having a half-life of less than two months and that are principally beta particle emitters, so that when activated, said stent emits low to moderate dosages of radiation uniformly to reduce cell proliferation.

Abstract: A method for treating bone metastases and like skeletal tumors in an individual which comprises treating said individual with a dose of a physiologically acceptable amount.

Abstract: Disclosed are radioactivatable compositions, preferably metal alloy compositions containing a metal having shape memory characteristics, and at least one radioactibatable isotope comprising a lanthanide series element or mixtures of lanthanide series of elements or other suitable isotope. The radioactivatable isotope is present in sufficient concentration (relative to other components of the composition) to deliver an effective radiation dose to a target tissue to achieve a specified therapeutic objective. One of the more advantageous and useful applications for this composition is the formation of medical devices for the treatment of coronary artery disease and the abatement of proliferation of cancer cells. In one of the embodiments of this invention, a radioactivatable isotope is incorporated, by isotopic beneficiated combination, with a matrix material such as nickel/titanium alloy (e.g.

Abstract: A metal stent for vascular implantation comprising a generally tubular structure whose external surface is adapted to engage the interior vascular surface when implanted, said metal of said stent containing a substantially uniform dispersion of from about 0.05 to about 10.00 percent by weight of one or more naturally occurring or enriched stable isotopes having a half-life of less than two months and that are principally beta particle emitters, so that when activated, said stent emits low to moderate dosages of radiation uniformly to reduce cell proliferation.